Being a health care professional in the ICU serving patients with covid-19: A qualitative studyResearch article Published on 2023-01-012022-10-05 Journal: Heart & lung : the journal of critical care [Category] 치료기술, [키워드] Anxiety approach being Care conducted COVID-19 COVID-19 pandemic Experiences explain Health health care providers Healthcare provider hospitalized patient ICU Infectious disease information intensive care intensive care unit Invasion management Nurse objective pandemic Pandemics participant Patient physical Physicians Psychological receive recruit Research Result risk the epidemic Turkey with COVID-19 [DOI] 10.1016/j.hrtlng.2022.07.011 [Article Type] Research article
Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humansArticle Published on 2022-12-052022-11-15 Journal: The Journal of Experimental Medicine [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] antibodies antibody Antigen antigenic breadth Breakthrough infection Cell comparable Delta develop dose Effect elicit Frequency Human increase increases in individual Infection memory memory B memory B cell memory B cells memory response Memory responses mRNA mRNA vaccine omicron plasma antibody receive response responses SARS-CoV-2 severe COVID-19 [DOI] 10.1084/jem.20221006 PMC 바로가기
Humoral responses after inactivated COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infection: A prospective cohort studyArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome antibody asymptomatic infections benefit blood sample booster dose Clinical severity collected coronavirus coronavirus disease COVID-19 COVID-19 vaccination detectable dose evaluated Evidence first dose humoral humoral immune response Humoral immunity Humoral response inactivated Inactivated COVID-19 vaccine individual individuals infected individuals Infection median mild cases moderate multicenter NAb titer NAbs naïve individual naïve individuals natural infection Neutralizing Neutralizing activity neutralizing antibody omicron pan-immunoglobulins. participant prospective cohort study Protein receive recovered patient SARS-CoV-2 second dose seroconversion rate severity significantly single dose single vaccine the vaccine U/mL vaccination variant [DOI] 10.1002/jmv.28055 PMC 바로가기
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trialArticle Published on 2022-12-012022-10-06 Journal: The Lancet Regional Health - Western Pacific [Category] 진단, [키워드] acute respiratory syndrome Administered Adults adverse event AEs age analysis assessment assigned BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine China Chinese clinical trial Complete Completed conducted coronavirus COVID-19 development dose double-blind Efficacy and safety enrolled Follow-up geometric mean titer GMT GMTs Han Chinese healthy immune response immunogenicity immunogenicity endpoint Inc independent individual injection intramuscular Intramuscular injection investigators Laboratory parameters management messenger Messenger RNA Mild moderate mRNA vaccine Neutralising Antibodies neutralising antibody of BNT162b2 participant Participants pharmaceutical Placebo placebo-controlled trial randomisation randomised Randomly reactogenicity receive recipients recruited reduced remained reported resolved Result robust Safety SARS-CoV-2 SARS-CoV-2 variant SCR second dose sera serious AE seroconversion rate severity Shanghai Sponsor statisticians stratified T-cell Response the placebo group Tolerability Treatment Trial utilised vaccination vaccination. vaccine administration were blinded [DOI] 10.1016/j.lanwpc.2022.100586 PMC 바로가기 [Article Type] Article
Treatment Strategies and Perforation Rate of Acute Appendicitis During the Early Phase of the Covid-19 Pandemic: A Swedish Cohort StudyResearch article Published on 2022-12-012022-10-05 Journal: The Journal of surgical research [Category] 치료법, [키워드] 95% confidence interval Acute appendicitis Appendicitis association calculate Care Conservative management COVID-19 COVID-19 pandemic diagnosed early phase Frequency initial less multivariate logistic regression Odds ratio pandemic Patient patients hospitalized Perforation Perforation rate phase Rate receive resource Result risk severity single-center study South Strategy surgical Swedish Treatment Treatment strategies [DOI] 10.1016/j.jss.2022.07.007 [Article Type] Research article
Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccinationArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome addition adenoviral-vectored vaccine antibody AZD1222 binding antibody BNT162b2 booster booster vaccination Booster vaccine comparable Complete coronavirus Coronavirus 2019 COVID-19 demonstrated develop dose Effect enrolled enzyme-linked immunosorbent Heterologous highest immune evasion immune response Immunogenicity analysis individual induce interferon-γ Messenger RNA Mild moderate mRNA mRNA vaccine mRNA-1273 mutations NAb titer NAbs neutralization neutralize Neutralizing Neutralizing activity neutralizing antibody observé Omicron variant Omicron. overcome participant raise receive receiving reduction response Serious Adverse Events significant increase Spike protein T-cell activation T-cell Response T-cell responses vaccination Vaccine waning immunity was recorded were measured [DOI] 10.1002/jmv.28044 PMC 바로가기
Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial재조합 인터페론 무장 융합 단백질 백신(V-01)을 사용한 SARS-CoV-2에 대한 이종 부스팅의 효능: 무작위, 이중 맹검 및 위약 대조 3상 시험Clinical Trial Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] adverse event antibody assigned booster clinical trial common adverse event conducted COVID-19 vaccine COVID-19 vaccines dose double-blind dramatic increase Efficacy elicit eligible fatigue Fever fusion protein groups headache healthy Heterologous heterologous boosting Humoral immunity Identifier Immunity inactivated Inactivated vaccine Inactivated Vaccines Inc injection injection site intention-to-treat principle Malaysia Mild-to-moderate Neutralizing Neutralizing antibodies occurred Older omicron Omicron variant over Pain participant Participants Placebo placebo-controlled primary endpoint Randomized Randomly receive regimen robust Safe SARS-CoV-2 SARS-COV-2 infection second dose Serious Adverse Events subunit Subunit vaccine Subunit vaccine. Surveillance symptomatic SARS-CoV-2 infection the epidemic titre Trial Trial registration V-01 Vaccine vaccine efficacy variant virus-neutralizing antibodies was measured were assessed [DOI] 10.1080/22221751.2022.2088406 PMC 바로가기 [Article Type] Clinical Trial
An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variantsSARS-CoV-2 오미크론 변이체에 감염된 중국 참가자의 VV116에 대한 공개, 전향적 코호트 연구Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] adjusted administration adverse event adverse events anti-SARS-CoV-2 antiviral drug baseline characteristics Chinese Cohort cohort study collected conducted control group COVID-19 Cox regression analysis effective Effectiveness Efficacy enrolled evaluate first positive Follow-up Hospitalized infected with SARS-CoV-2 Infection Intervention median time no significant difference omicron Omicron variant participant Patient preclinical studies predominant Prevalence prospective cohort study receive regression analysis reported resolved robust Safe Serious Adverse Event Serious Adverse Events standard treatment Symptom symptomatic treatment group variant variant of SARS-CoV-2 Viral load Viral load. viral shedding VV116 with COVID-19 [DOI] 10.1080/22221751.2022.2078230 PMC 바로가기 [Article Type] Article
Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trialArticle Published on 2022-11-082022-11-16 Journal: Trials [Category] SARS, 변종, [키워드] adaptive anti-COVID-19 IVIG antivirals clinical evidence clinical trial collected convalescent convalescent plasma COVID-19 cumulative death Efficacy eligibility criteria evaluate Health hyperimmune immunization immunomodulators intravenous Intravenous immunoglobulin low dose monoclonal antibodies Neutralizing non-specific novel Novel coronavirus outcome Passive passive immunization Patient phase Pneumonia polyclonal polyclonal antibodies Pooled convalescent plasma Potential treatment Randomized Randomized controlled trial receive Recovered COVID-19 patients reported SARS CoV-2 SARS CoV-2. SARS-CoV-2 sealed Secondary outcomes severe COVID-19 severe COVID-19 patient severe COVID-19 patients Standard of care Steroids Study protocol therapeutic option therapy treat Treatment Trial variant variants of concern virus virus particles World Health Organization [DOI] 10.1186/s13063-022-06860-2 PMC 바로가기
COVID-19 vaccine hesitancy in periconceptional and lactating women: a systematic review and meta-analysis protocolArticle Published on 2022-11-072022-11-16 Journal: BMJ Open [Category] meta-analysis, [키워드] Analysis appear approval article caused CNKI Cochrane Library COVID-19 COVID-19 vaccine criteria data extraction determinant discrepancy disease effective Embryology Epidemiology Ethics Evidence gestation heterogeneity higher risk homogeneous indicated lack lactating lactating women lactation Meta-analysis meta-regression observational study outcome outcomes pandemic pandemic of COVID-19 peer-reviewed Pregnancy pregnant pregnant women Prevalence PROSPERO protocol provided receive reproductive Reproductive medicine. required Research resolved subject systematic review vaccination Vaccine hesitancy Web of Science WHO with COVID-19 women [DOI] 10.1136/bmjopen-2021-059514 PMC 바로가기